Skip to main
HRMY
HRMY logo

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 53%
Buy 33%
Hold 0%
Sell 7%
Strong Sell 7%

Bulls say

Harmony Biosciences Holdings Inc. demonstrates a promising growth outlook, highlighted by WAKIX's robust revenue performance, which reached $201.3 million in net sales during the fourth quarter of 2024, reflecting a 20% year-over-year increase. The company anticipates a significant upward trajectory in WAKIX sales, projecting growth from approximately $160 million in 2020 to greater than $700 million in 2024, driven by strong adoption among prescribers and a competitive safety profile. Additionally, Harmony's pipeline, including promising drug candidates targeting rare neurological conditions, positions the company to further enhance its growth potential and capitalize on unmet medical needs in the market.

Bears say

Harmony Biosciences Holdings Inc. faces significant challenges affecting its financial outlook, primarily stemming from the potential entry of new competitors in the sodium oxybate market, which could hinder the growth of its primary product, WAKIX. The company has also expressed concerns regarding the potential slowdown in new patient additions for WAKIX, as well as the uncertainty surrounding the success of its ongoing clinical trials for various drug candidates, which are essential for future growth. Additionally, the expectation of earlier-than-anticipated competition from generic pitolisant has compelled the company to adjust its estimated revenues, leading to a $5 reduction in the estimated value of the pitolisant pipeline and a corresponding decrease in the price target from $75 to $70.

HRMY has been analyzed by 15 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 15 analysts, HRMY has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.